Amp Volatility Score
Catalyst Info & Data Links
TITLE: Relacorilant for Hypercortisolism (Cushing Syndrome) - Phase 3
ClinicalTrial.gov (NCT03697109): A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE)
WHAT IS THE NEXT CATALYST EVENT?
NDA Submission Based on Results
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
2Q 2022 (Q3 2020 Financial Update)
11-03-2020 2020 Third Quarter Financial Results
2020: GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
MECHANISM OF ACTION
Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, one of the two receptors to which cortisol binds. Relacorilant does not bind to the body's other hormone receptors, including the progesterone receptor. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders.
Updated by JM
CORT, Hypercortisolism (Cushing Syndrome), Korlym®(Relacorilant), Corcept Therapeutics
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post